^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | IK-930 (TEAD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IK930, a novel TEAD inhibitor, sensitizes KRAS and EGFR mutant tumors to oncogene targeted therapy
Published date:
10/12/2022
Excerpt:
Consistently, combination of IK-930 with MEKi and EGFRi resulted in apoptosis in vitro and led to strong antitumor activity in vivo in KRAS and EGFR mutant xenografts models of CRC and NSCLC.
Secondary therapy:
MEK inhibitor; EGFR inhibitor
